[A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients].

摘要: Background and objective Platinum-based chemotherapy is considered the standard treatment of advanced non-small cell lung cancer (NSCLC). The aim this study to evaluate efficacy safety gemcitabine plus oxaliplatin (GO) versus cisplatin (GP) regimens as 1st line for elderly patients with NSCLC. Methods Sixty-six NSCLC confirmed pathology or cytology, who had not received treatment, were randomly divided into GO group (The 1,000 mg/m2 on day 1 8 130 by intravenous infusion, 21 days one cycle) GP 25 1, 2 3) cycle). All more cycles could be evaluated. Results There no statistical differences between groups in efficiency disease (36.4% vs 40.6%, P=0.801), median progression-free survival (24 weeks 18 weeks, P=0.565), time (44 36 P=0.918), but anemia at grade III IV (0 33.3%, P < 0.001) nausea/vomiting 27.3%, P=0.004) significantly different. Conclusion clinical was similar, toxicity regimen has tendency tolerable safer. DOI: 10.3779/j.issn.1009-3419.2011.07.05